Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy

Audrey Bellesoeur, Edith Carton, Jerome Alexandre, Francois Goldwasser, Olivier Huillard Department of Medical Oncology, Hopital Cochin AP-HP, Paris, France Abstract: Since 2005, the approved first-line treatment of metastatic renal cell carcinoma consists in tyrosine kinase inhibitors (TKIs) targ...

Full description

Bibliographic Details
Main Authors: Bellesoeur A, Carton E, Alexandre J, Goldwasser F, Huillard O
Format: Article
Language:English
Published: Dove Medical Press 2017-09-01
Series:Drug Design, Development and Therapy
Subjects:
renal cell carcinoma
tyrosine kinase inhibitors
vascular endothelial growth factor
axitinib
pharmacology
Online Access:https://www.dovepress.com/axitinib-in-the-treatment-of-renal-cell-carcinoma-design-development-a-peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/axitinib-in-the-treatment-of-renal-cell-carcinoma-design-development-a-peer-reviewed-article-DDDT

Similar Items